254 related articles for article (PubMed ID: 16859393)
21. Do the Natural Chemical Compounds Interact with the Same Targets of Current Pharmacotherapy for Weight Management?-A Review.
Luo S; Lenon GB; Gill H; Yuen H; Yang AWH; Hung A; Nguyen LT
Curr Drug Targets; 2019; 20(4):399-411. PubMed ID: 30173643
[TBL] [Abstract][Full Text] [Related]
22. [The pharmacological treatment of obesity: past, present and future].
Simonyi G; Pados G; Medvegy M; Bedros JR
Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224
[TBL] [Abstract][Full Text] [Related]
23. Chronic gastric electrical stimulation leads to weight loss via modulating multiple tissue neuropeptide Y, orexin, α-melanocyte-stimulating hormone and oxytocin in obese rats.
Yan Y; Tian L; Xiang X; Ding W; Song G; Xu J
Scand J Gastroenterol; 2016; 51(2):157-67. PubMed ID: 26199984
[TBL] [Abstract][Full Text] [Related]
24. Obesity drug pipeline not so fat.
Gura T
Science; 2003 Feb; 299(5608):849-52. PubMed ID: 12574616
[No Abstract] [Full Text] [Related]
25. Decreased plasma ghrelin contributes to anorexia following novelty stress.
Saegusa Y; Takeda H; Muto S; Nakagawa K; Ohnishi S; Sadakane C; Nahata M; Hattori T; Asaka M
Am J Physiol Endocrinol Metab; 2011 Oct; 301(4):E685-96. PubMed ID: 21712530
[TBL] [Abstract][Full Text] [Related]
26. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
[TBL] [Abstract][Full Text] [Related]
27. Experimental drugs take aim at obesity.
Vastag B
JAMA; 2003 Apr; 289(14):1763-4. PubMed ID: 12684341
[No Abstract] [Full Text] [Related]
28. Heterodimerization of hypothalamic G-protein-coupled receptors involved in weight regulation.
Rediger A; Tarnow P; Bickenbach A; Schaefer M; Krude H; Gruters A; Biebermann H
Obes Facts; 2009; 2(2):80-6. PubMed ID: 20054210
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
Hodge RJ; Nunez DJ
Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
[TBL] [Abstract][Full Text] [Related]
30. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
Mashiko S; Moriya R; Ishihara A; Gomori A; Matsushita H; Egashira S; Iwaasa H; Takahashi T; Haga Y; Fukami T; Kanatani A
Eur J Pharmacol; 2009 Aug; 615(1-3):113-7. PubMed ID: 19482021
[TBL] [Abstract][Full Text] [Related]
31. Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse.
Dalton GL; Lee MD; Kennett GA; Dourish CT; Clifton PG
Psychopharmacology (Berl); 2006 Mar; 185(1):45-57. PubMed ID: 16470405
[TBL] [Abstract][Full Text] [Related]
32. Promising new approaches to the management of obesity.
Mertens IL; Van Gaal LF
Drugs; 2000 Jul; 60(1):1-9. PubMed ID: 10929926
[TBL] [Abstract][Full Text] [Related]
33. Hypothalamic regulatory pathways and potential obesity treatment targets.
Jobst EE; Enriori PJ; Sinnayah P; Cowley MA
Endocrine; 2006 Feb; 29(1):33-48. PubMed ID: 16622291
[TBL] [Abstract][Full Text] [Related]
34. A Positive Allosteric Modulator of the Serotonin 5-HT
García-Cárceles J; Decara JM; Vázquez-Villa H; Rodríguez R; Codesido E; Cruces J; Brea J; Loza MI; Alén F; Botta J; McCormick PJ; Ballesteros JA; Benhamú B; Rodríguez de Fonseca F; López-Rodríguez ML
J Med Chem; 2017 Dec; 60(23):9575-9584. PubMed ID: 29116785
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question.
Zhao H; Liu G
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):509-15. PubMed ID: 16889233
[TBL] [Abstract][Full Text] [Related]
36. Treating obesity: does antagonism of NPY fit the bill?
Farooqi S
Cell Metab; 2006 Oct; 4(4):260-2. PubMed ID: 17011498
[TBL] [Abstract][Full Text] [Related]
37. Computer-aided identification of ligands for GPCR anti-obesity targets.
Min KH; Yoo J; Park HJ
Curr Top Med Chem; 2009; 9(6):539-53. PubMed ID: 19689364
[TBL] [Abstract][Full Text] [Related]
38. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
Yeo GSH; Chao DHM; Siegert AM; Koerperich ZM; Ericson MD; Simonds SE; Larson CM; Luquet S; Clarke I; Sharma S; Clément K; Cowley MA; Haskell-Luevano C; Van Der Ploeg L; Adan RAH
Mol Metab; 2021 Jun; 48():101206. PubMed ID: 33684608
[TBL] [Abstract][Full Text] [Related]
39. Obesity: new perspectives and pharmacotherapies.
Palamara KL; Mogul HR; Peterson SJ; Frishman WH
Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
[TBL] [Abstract][Full Text] [Related]
40. Obesity: Current Treatment and Future Horizons.
Omran Z
Mini Rev Med Chem; 2017; 17(1):51-61. PubMed ID: 27320641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
